Results from our content library
AI-Powered Search
Sign in to search for any topic in our content library — get summaries, related past year questions, and practice MCQs on the topic.
Sign in to searchIndia’s First Approved Pluvicto Radioligand Therapy
India has recently approved Pluvicto (Lutetium-177 vipivotide tetraxetan), the country's first regulatory-approved Radioligand Therapy (RLT) for the treatment of advanced prostate cancer. Developed by Novartis India
Sign up free to read the full article
Free accounts include 5 articles every month across current affairs, state notes, subject notes and more — upgrade anytime for unlimited access.
India approves Pluvicto, its first radioligand therapy for advanced prostate cancer. Novartis-developed treatment targets PSMA-positive mCRPC with precision medicine.
Keywords